Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

36.92 +0.12 (+0.33%)
Streaming Delayed Price Updated: 11:49 AM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alkermes plc - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
From Alkermes plc
Via Business Wire
News headline image
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
From Alkermes plc
Via Business Wire
News headline image
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
From Alkermes plc
Via Business Wire
News headline image
Alkermes Honors Women's Equality Day
Via ACCESSWIRE
News headline image
Alkermes plc Reports First Quarter 2026 Financial Results
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Report First Quarter Financial Results on May 5, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
From Alkermes plc
Via Business Wire
News headline image
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
From Alkermes plc
Via Business Wire
News headline image
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
From Alkermes plc
Via Business Wire
News headline image
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
From Alkermes plc
Via Business Wire
News headline image
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes plc Announces CEO Succession Plan
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
From Alkermes plc
Via Business Wire
News headline image
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
From Alkermes plc
Via Business Wire
News headline image
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Participate in Two Upcoming Investor Conferences
From Alkermes plc
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avadel Pharmaceuticals plc (Nasdaq – AVDL), Middlefield Banc Corp. (Nasdaq – MBCN), Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders
From Sarissa Capital Management LP
Via Business Wire
News headline image
Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Capital Comments on Alkermes Annual Meeting
From Sarissa Capital Management LP
Via Business Wire
News headline image
Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
SOURCE: Alkermes 
Via 3BL Media
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.